Chemed Q2 adjusted EPS $5.47 (+34.1% YoY); raises FY2024 guidance to $23.55-$23.80

CHEMED CORP

2024-Q2 EPS reported $8.89 revenue$1,185,113,000

Revenue $595.9M (+7.6%); GAAP EPS $4.65 (+32.5%); adjusted EPS $5.47 (+34.1%).
VITAS net patient revenue +16.7% to $374.6M; ADC +14.4% to 21,036; adjusted EBITDA +77% to $67.0M.
Roto-Rooter revenue -5% to $221.3M; adjusted EBITDA -9.2% to $59.8M; margin 27.0%.
FY2024 adjusted EPS guidance raised to $23.55-$23.80 (from $23.30-$23.70); VITAS EBITDA margin 19.3%-19.7%.
Repurchased 100k shares for $55.8M; cash $222.9M, no debt; $225.9M remaining buyback authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.